| HUMAN-TRIAL | evidence | Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia | Tesamorelin | human-rct | — |
| HUMAN-TRIAL | evidence | Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury | Egrifta | Neuroprotection · human-rct · n = 36 | — |
| HUMAN-TRIAL | evidence | Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® | Tesamorelin | human-observational · n = 391 | — |
| REGULATORY | regulatory | EGRIFTA SV — FDA prescribing information | FDA | — | 2025-12-23 |
| REGULATORY | regulatory | D-0088-2026 — Tesamorelin for Injection, 15mg, 10 mL Multi-Dose Vial, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. | FDA | — | 2025-07-30 |
| REGULATORY | regulatory | EGRIFTA WR — FDA prescribing information | FDA | — | 2025-03-31 |
| REGULATORY | regulatory | D-0223-2019 — Tesamorelin, 1mg/vial, 6mL vial, Lyophilized Powder for Reconstitution and Subcutaneous Injection, Rx Only, Tailor Made Compounding, Nicholasville, KY 40356 | FDA | — | 2018-09-28 |
| REGULATORY | regulatory | EGRIFTA WR — FDA application BLA022505 | FDA | — | 2010-11-10 |
| ANIMAL | evidence | Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model. | Tesamorelin | animal | 2026-01-01 |
| ANIMAL | evidence | Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. | TH9507 | Growth hormone axis · animal | 2007-01-01 |
| ANIMAL | evidence | Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. | TH9507 | Growth hormone axis · animal | 2004-05-19 |
| PRECLINICAL | evidence | The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. | Tesamorelin | — | 2026-09-01 |
| PRECLINICAL | evidence | Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. | Tesamorelin | Growth hormone axis · n = 100 | 2026-07-08 |
| PRECLINICAL | evidence | Selected Industry Highlights From IDWeek 2025. | Tesamorelin | Weight & fat loss | 2026-05-15 |
| PRECLINICAL | evidence | Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. | Tesamorelin | Weight & fat loss | 2026-05-15 |
| PRECLINICAL | evidence | Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. | Tesamorelin | — | 2026-05-01 |
| PRECLINICAL | evidence | Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. | Tesamorelin | — | 2026-04-27 |
| PRECLINICAL | evidence | Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. | Egrifta | — | 2026-04-12 |
| PRECLINICAL | evidence | Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. | Tesamorelin | Growth hormone axis | 2026-01-15 |
| PRECLINICAL | evidence | Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss. | Tesamorelin | — | 2026-01-09 |
| PRECLINICAL | evidence | Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. | Tesamorelin | — | 2026-01-01 |
| PRECLINICAL | evidence | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. | Tesamorelin | Wound healing | 2026-01-01 |
| PRECLINICAL | evidence | The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. | Tesamorelin | Growth hormone axis | 2026-01-01 |
| PRECLINICAL | evidence | Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. | Tesamorelin | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Metabolic dysfunction-associated steatotic liver disease in people with HIV. | Tesamorelin | Liver health | 2025-07-01 |
| PRECLINICAL | evidence | Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study. | Tesamorelin | — | 2025-05-01 |
| PRECLINICAL | evidence | CROI 2024: Neuropsychiatric Complications in People With HIV. | Tesamorelin | — | 2024-08-12 |
| PRECLINICAL | evidence | Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. | Tesamorelin | Growth hormone axis | 2024-01-01 |
| PRECLINICAL | evidence | Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome. | Tesamorelin | Lipid & cardiovascular markers | 2024-01-01 |
| PRECLINICAL | evidence | Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples. | Tesamorelin | — | 2023-12-01 |
| PRECLINICAL | evidence | Proteomic Analysis of Hepatic Fibrosis in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease Demonstrates Up-regulation of Immune Response and Tissue Repair Pathways. | Tesamorelin | Immune function | 2023-02-14 |
| PRECLINICAL | evidence | Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. | Tesamorelin | — | 2023-01-01 |
| PRECLINICAL | evidence | Causes and outcomes of hepatic fibrosis in persons living with HIV. | Tesamorelin | Liver health | 2022-11-01 |
| PRECLINICAL | evidence | Probing for peptidic drugs (2-10 kDa) in doping control blood samples. | Tesamorelin | — | 2022-08-01 |
| PRECLINICAL | evidence | An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. | Tesamorelin | Growth hormone axis | 2022-05-30 |
| PRECLINICAL | evidence | Approach to the Patient With Lipodystrophy. | Tesamorelin | Weight & fat loss | 2022-05-17 |
| PRECLINICAL | evidence | Advances in the detection of growth hormone releasing hormone synthetic analogs. | Tesamorelin | Growth hormone axis · preclinical | 2021-11-01 |
| PRECLINICAL | evidence | Tesamorelin improves fat quality independent of changes in fat quantity. | Tesamorelin | — | 2021-07-15 |
| PRECLINICAL | evidence | Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. | Tesamorelin | Growth hormone axis | 2021-05-18 |
| PRECLINICAL | evidence | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | Tesamorelin | Inflammation | 2021-01-01 |
| PRECLINICAL | evidence | Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. | Tesamorelin | Growth hormone axis | 2020-11-08 |
| PRECLINICAL | evidence | Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation. | Tesamorelin | — | 2020-01-15 |
| PRECLINICAL | evidence | Tesamorelin, liver fat, and NAFLD in the setting of HIV. | Tesamorelin | Growth hormone axis | 2019-12-01 |
| PRECLINICAL | evidence | Cardiovascular risk and dyslipidemia among persons living with HIV: a review. | Tesamorelin | Lipid & cardiovascular markers | 2017-08-09 |
| PRECLINICAL | evidence | Growth hormone deficiency and human immunodeficiency virus. | Tesamorelin | Growth hormone axis | 2017-02-01 |
| PRECLINICAL | evidence | Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. | Tesamorelin | Neuroprotection | 2016-10-01 |
| PRECLINICAL | evidence | | Egrifta | — | 2016-08-01 |
| PRECLINICAL | evidence | Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. | Egrifta | Growth hormone axis | 2016-05-01 |
| PRECLINICAL | evidence | Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. | Tesamorelin | — | 2015-11-01 |
| PRECLINICAL | evidence | Treatment of dyslipidemia in HIV. | Tesamorelin | Lipid & cardiovascular markers | 2015-04-01 |